FEED — what changed in the latest 10-Q
A section-by-section comparison of FEED's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-17 vs the prior 10-Q · 2026-05-18
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +38 | −17 | ~13 | 5 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 4 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 3 |
| Risk factors | Text added/removed | +12 | 0 | 0 | 1 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-17
Following the ENvue Merger, the Company has progressively consolidated certain functions and resources across the combined organization in order to reduce duplication and improve operating efficiency. This has included the sharing of personnel and technical resources across the Company’s two product…
Three Months Ended June 30, 2026, Compared to Three Months Ended June 30, 2025
Revenues. For the three months ended June 30, 2026, and 2025, our revenues were approximately $239 and $494, respectively, a decrease of approximately 51.6%, or $255, between the periods. The decrease was primarily attributable to a halt in production of our PainShield/UroShield products resulting f…
This decline was partially offset by growth in ENvue revenues, which increased by approximately 275%, from approximately $49 to approximately $184, driven by continued expansion of our installed hospital base and adoption of the ENvue Navigation Platform. We also continued to generate revenues throu…
For the three months ended June 30, 2026, the percentage of revenues attributable to our products was: 16% for PainShield and monthly kits, 2% for UroShield and monthly kits, 77% for ENvue systems and tubes and 5% for other products. For the three months ended June 30, 2025, the percentage of revenu…
Text removed vs the prior filing · source: 10-Q · 2026-05-18
Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025
Revenues. For the three months ended March 31, 2026, and 2025, our revenues were approximately $653 and $1,025, respectively, a decrease of approximately 36%, or $372, between the periods. The decrease was primarily attributable to the removal of PainShield Ultra from the market, partially offset by…
For the three months ended March 31, 2026, the percentage of revenues attributable to our products was: 82% for PainShield and monthly kits and 18% for ENvue system and tubes. For the three months ended March 31, 2025, the percentage of revenues attributable to our products was: 85 % for PainShield …
Gross Profit (Loss). For the three months ended March 31, 2026, and 2025, gross profit (loss) was approximately ($55) and $369, respectively, a decrease of approximately 115% or $424. Gross margin was also significantly impacted, declining primarily due to the removal of PainShield Ultra from the ma…
Gross profit as a percentage of revenues were approximately (11%) and 36% for the three months ended March 31, 2026, and 2025, respectively. The decrease in gross profit as a percentage of revenues is mainly due to the reasons described above.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-17
If we fail to comply with the continued listing requirements of Nasdaq, our Common Stock may be delisted and the price of our Common Stock and our ability to access the capital markets could be negatively impacted.
Our Common Stock is currently listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum stockholders’ equity of $2.5 million and a minimum closing bid price of $1.00 per share or risk delisting, which would have a material adverse…
On July 10, 2026, we received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that the Staff has determined that the closing bid price of our Common Stock has been below $1.00 per share for th…
On April 10, 2024, we received the Letter from the Staff of Nasdaq indicating that, based upon the closing bid price of our Common Stock for the 30 consecutive business days between February 27, 2024 and April 9, 2024, we did not meet the minimum bid price of $1.00 per share required for continued l…
On November 19, 2024, we received an additional deficiency notice from the Staff indicating that we no longer satisfied the $2.5 million stockholders’ equity requirement set forth in the Equity Rule for continued listing on Nasdaq. The Staff indicated that our non-compliance with the Equity Rule wou…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice